Lipocine Inc.

$2.3 ▼ -77.84%

2026-04-21 07:57:00

Explore Lipocine Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.

Market Cap

$16.86 M

Current Price

$2.3

52W High / Low

$12.37 / $1.81

Stock P/E

—

Book Value

$2.35

Dividend Yield

—

ROCE

-71.64%

ROE

-54.28%

Face Value

—

EPS

$-1.77

Exp Qtr EPS

—

Sector

Healthcare

Industry

Biotechnology

Employees

14

Beta

1.09

Debt / Equity

3.1

Current Ratio

6.68

Quick Ratio

6.68

Forward P/E

-1.77

Price / Sales

8.12

Enterprise Value

$1.58 M

EV / EBITDA

-0.15

EV / Revenue

0.8

Rating

Buy

Target Price

$11

EPS Forecast (FY)

—

ABOUT

In essence, lipocine Inc., a clinical-stage biopharmaceutical This organization, is actively involved in the research and development for the delivery of drugs using its proprietary delivery technology. In essence, this organization delivers TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. In essence, it also is focused on developing LPCN 1154 (BRLIZIO), an oral neuro-steroid in a Phase 3 pivotal trial for postpartum depression; LPCN 1148, a prodrug of testosterone and testosterone laurate that has completed a Phase 2 trial for the management of decompensated cirrhosis; LPCN 1107, an oral hydroxy progesterone caproate product that has completed a Phase 2 trial for the prevention of recurrent preterm birth; LPCN 1144, an oral prodrug of bioidentical testosterone that has completed a Phase 2 trial for pre-cirrhotic non-alcoholic steatohepatitis; and LPCN 2401, an oral formulation comprising a proprietary anabolic androgen receptor agonist that is in a Phase 2 trial to manage incretin mimetic use in obesity management. In essence, in addition, This organization is developing LPCN 2201, an oral brexanolone formulation that has completed a Phase 1 trial for major depressive disorders; LPCN 2203, an oral candidate that has completed a Phase 1 trial for management of essential tremor; and LPCN 2101, a neuroactive steroids (NAS) candidate that has completed a Phase 1 trial for drug-resistant epilepsy and women with epilepsy. In essence, this organization's products focus on neurological and psychiatric central nervous system (CNS) disorders, liver disease, and hormone supplementation in the United States. In essence, it has a collaboration with Verity Pharmaceuticals, Inc. In essence, to develop and commercialize TLANDO; and TLANDO XR (LPCN 1111), a once-daily oral product candidate that has completed a Phase 2 trial for testosterone replacement therapy. Lipocine Inc. In essence, was founded in 1997 and is headquartered in Salt Lake City, Utah. ROE at -54.28% based on the latest available annual data. ROCE at -71.64% using operating income and capital employed. Debt to equity stands at nanx. Operating margin is -219.65% on trailing numbers. Trailing twelve month sales are available in the dataset.

Pros

Short-term liquidity looks comfortable.
Valuation is not stretched on P/E basis.

Cons

Return on equity is on the weaker side.
Capital efficiency is modest.
Operating margin is thin.
Net margin is relatively low.

Sift Stocks

S.No.	Name	Price	P.E.	Market Cap	Div Yld %	ROCE	ROE	52Week High/ Low	Book Value
1.	GH Research PLC	$21.5	—	$1.33 B	—	-21.68%	-21.04%	$24.66 / $8.66	$4.51
2.	Senti Biosciences, Inc.	$1.14	—	$34.26 M	—	-171.08%	-2.18%	$5.1 / $0.77	$0.18
3.	Maravai LifeSciences Holdings, Inc.	$3.61	—	$928.01 M	—	-17.71%	-48.59%	$4.11 / $1.67	$1.46
4.	Aardvark Therapeutics, Inc.	$5.65	—	$114.1 M	—	-58.82%	-64.44%	$17.94 / $3.35	$4.89
5.	Whitehawk Therapeutics, Inc.	$4.23	—	$193.98 M	—	-83.93%	-21.82%	$4.48 / $1.39	$2.89
6.	Ensysce Biosciences, Inc.	$0.48	—	$4.49 M	—	-355%	-3.25%	$4.85 / $0.31	$0.7
7.	Aurinia Pharmaceuticals Inc.	$15.96	7.38	$2.12 B	—	16.2%	59.91%	$16.54 / $7.29	$4.39

Quarterly Results

Figures shown in M / B

	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024
Sales	1.15 M	0.11 M	0.62 M	0.09 M	3.49 M	—
Operating Profit	-2.52 M	-3.36 M	-2.4 M	-2.09 M	1.55 M	—
Net Profit	-2.37 M	-3.19 M	-2.21 M	-1.86 M	1.78 M	—
EPS in Rs	-0.32	-0.44	-0.3	-0.26	0.24	-0.44

Profit & Loss

Figures shown in M / B

	2025	2024	2023	2022
Sales	1.98 M	11.2 M	-2.85 M	0.5 M
Operating Profit	-10.37 M	-1.16 M	-17.93 M	-12.12 M
Net Profit	-9.63 M	0.01 M	-16.35 M	-10.76 M
EPS in Rs	-1.32	0	-2.24	-1.47

Balance Sheet

Figures shown in M / B

	2025	2024	2023	2022
Total Assets	17.01 M	22.51 M	23 M	37.54 M
Total Liabilities	2.53 M	1.51 M	2.63 M	1.91 M
Equity	14.48 M	21 M	20.37 M	35.63 M
Current Assets	16.88 M	22.32 M	22.86 M	34.14 M
Current Liabilities	2.53 M	1.51 M	2.63 M	1.68 M

Cash Flow

Last available yearly cash flow history

	2025	2024	2023	2022
Operating CF	-9.76 M	-1.22 M	-11.87 M	-11.97 M
Investing CF	5.89 M	2.45 M	13.08 M	14.29 M
Financing CF	2.87 M	0.21 M	0.4 M	-2.13 M
Free CF	-9.76 M	-1.31 M	-11.88 M	-12.1 M
Capex	—	-0.09 M	-0.01 M	-0.13 M

5Y Margin & Growth History

Last 5 year derived history from yfinance annual statements

	2024	2023	2022	2021
Revenue Growth %	492.8%	-670.16%	—	—
Earnings Growth %	100.05%	-51.99%	—	—
Profit Margin %	0.07%	573.59%	-2151.73%	—
Operating Margin %	-10.31%	628.98%	-2423.88%	—
Gross Margin %	34.35%	456.92%	-1611.38%	—
EBITDA Margin %	-9.95%	627.97%	-2144.28%	—

Dividend & Split History

Latest dividend and stock split events stored from yfinance

Dividend History

No dividend history available.

Stock Splits

Date	Split
2023-05-12	1:0.0588235

Shareholding Pattern

Shares and value shown in M / B

Holder Name	Type	Shares	Value	% Out	Report Date
Mink Brook Asset Management LLC	Institutional	0.07 M	$0.14 M	0.01%	2026-03-31
Fidelity Concord Street Trust-Fidelity Extended Market Index Fund	Mutual Fund	0.03 M	$0.06 M	0%	2026-02-28
Fidelity Concord Street Trust-Fidelity Total Market Index Fund	Mutual Fund	0.01 M	$0.02 M	0%	2026-02-28
Fidelity Concord Street Trust-Fidelity Series Total Market Index Fund	Mutual Fund	0.01 M	$0.02 M	0%	2026-02-28
Fidelity Concord Street Trust-Fidelity Nasdaq Composite Index Fund	Mutual Fund	0 M	$0.01 M	0%	2026-02-28
SCHWAB CAPITAL TRUST-Schwab Total Stock Market Index Fund	Mutual Fund	0 M	$0.01 M	0%	2026-01-31
DFA INVESTMENT DIMENSIONS GROUP INC-U.S. Social Core Eqy. 2 PORT.	Mutual Fund	0 M	$0.01 M	0%	2026-01-31
Dimensional ETF Trust-Dimensional US Sustainability Core 1 ETF	Mutual Fund	0 M	$0.01 M	0%	2026-01-31
Squadron Capital Management LLC	Institutional	0.53 M	$1.09 M	0.07%	2025-12-31
Diadema Partners LP	Institutional	0.26 M	$0.53 M	0.04%	2025-12-31
Vanguard Group Inc	Institutional	0.22 M	$0.45 M	0.03%	2025-12-31
Ikarian Capital, LLC	Institutional	0.2 M	$0.41 M	0.03%	2025-12-31
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund	Mutual Fund	0.14 M	$0.29 M	0.02%	2025-12-31
Blackrock Inc.	Institutional	0.09 M	$0.18 M	0.01%	2025-12-31
Persistent Asset Partners Ltd	Institutional	0.07 M	$0.14 M	0.01%	2025-12-31